Literature DB >> 6532180

The usability of the MRL/1 mouse strain in detection of anti-rheumatic drugs.

M L Toivonen, I B Lindén, M Gripenberg, H Vapaatalo.   

Abstract

D-Penicillamine (5 mg/kg), prednisolone (0.5 mg/kg), tolfenamic acid and thiabendazole (10 mg/kg) were chronically administered to male and female mice of MRL/1 strain. The treatment was started either at 4 weeks of age (prophylactic dosing) or at 12 weeks of age (therapeutic dosing) and continued until the termination at 24 weeks of age. In male mice all the drugs caused a significant retardation in IgM-RF formation with one of the dosing regimes. D-Penicillamine and prednisolone also had an inhibitory effect on lymph node enlargement. In female mice, however, only thiabendazole retarded the RF activity significantly. None of the drugs had any marked effect on anti-ssDNA antibody formation, and none of the treatments affected the development of renal disease or modified the survival of these mice.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6532180     DOI: 10.1007/bf01966777

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  20 in total

1.  Penicillamine in experimental models of immunologically mediated inflammation.

Authors:  E Arrigoni-Martelli
Journal:  Agents Actions Suppl       Date:  1979

Review 2.  Models of arthritis and the search for anti-arthritic drugs.

Authors:  M E Billingham
Journal:  Pharmacol Ther       Date:  1983       Impact factor: 12.310

3.  A simple enzyme immunoassay for the demonstration of rheumatoid factor.

Authors:  M Gripenberg; F Wafin; H Isomäki; E Linder
Journal:  J Immunol Methods       Date:  1979       Impact factor: 2.303

4.  Therapeutic studies in New Zealand mice. VII. Successful androgen treatment of NZB/NZW F1 females of different ages.

Authors:  K A Melez; W A Boegel; A D Steinberg
Journal:  Arthritis Rheum       Date:  1980-01

5.  Thiabendazole (TBZ), an immunohemomodulator. I. Effects on lymph node and spleen.

Authors:  E Donskaya; J Lundy; R Simon; I Goldschneider
Journal:  Int J Immunopharmacol       Date:  1982

6.  Rat adjuvant arthritis as a model to test potential antirheumatic agents.

Authors:  M L Toivonen; O Tokola; H Vapaatalo
Journal:  Methods Find Exp Clin Pharmacol       Date:  1982 Aug-Sep

7.  In vivo suppression of delayed hypersensitivity by thiabendazole and diethylcarbamazine.

Authors:  E L Hewlett; O Y Hamid; J Ruffier; A A Mahmoud
Journal:  Immunopharmacology       Date:  1981-12

8.  Effects of thymectomy or androgen administration upon the autoimmune disease of MRL/Mp-lpr/lpr mice.

Authors:  A D Steinberg; J B Roths; E D Murphy; R T Steinberg; E S Raveche
Journal:  J Immunol       Date:  1980-08       Impact factor: 5.422

9.  Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains.

Authors:  B S Andrews; R A Eisenberg; A N Theofilopoulos; S Izui; C B Wilson; P J McConahey; E D Murphy; J B Roths; F J Dixon
Journal:  J Exp Med       Date:  1978-11-01       Impact factor: 14.307

10.  A spontaneous rheumatoid arthritis-like disease in MRL/l mice.

Authors:  L Hang; A N Theofilopoulos; F J Dixon
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307

View more
  5 in total

1.  The anti-inflammatory pharmacologic profile of CGP 28237 (5-methylsulfonylamino-6-phenoxy-1-indanone).

Authors:  I Böttcher; B Jagher; C Rordorf-Adam; M Grüninger
Journal:  Agents Actions       Date:  1987-08

2.  Effects of LS-2616 administration upon the autoimmune disease of (NZB x NZW) F1 hybrid mice.

Authors:  A Tarkowski; K Gunnarsson; T Stålhandske
Journal:  Immunology       Date:  1986-12       Impact factor: 7.397

3.  Effects of immunomodulating treatment on autoimmune sialadenitis in MRL/Mp-lpr/lpr mice.

Authors:  R Jonsson; A Tarkowski; K Bäckman
Journal:  Agents Actions       Date:  1988-12

4.  Long-term treatment of the MRL/lpr mouse with methotrexate and 10-deazaaminopterin.

Authors:  J E Baggott; S L Morgan; L E Freeberg; B B Hudson; W H Vaughn; M Gopal Nair; C L Krumdieck; W J Koopman; R E Gay; S Gay
Journal:  Agents Actions       Date:  1992-01

5.  Effect of etodolac, a new nonsteroidal anti-inflammatory drug, in MRL/lpr mice with articular lesions.

Authors:  H Yoshida-Suzuka; Y Nakamura; Y Shibata; K Kimura
Journal:  Agents Actions       Date:  1991-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.